Glaukos Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GKOS | SGHT | 4548.T | REG1V.HE | IRIX | 4576.T | |
|---|---|---|---|---|---|---|
| Market cap | 14.60B | 533.25M | 31.12B | 453.80M | 12.56M | 3.11B |
| P/E (TTM) | — | — | 18.7 | 26.3 | — | — |
| Forward P/E | 176.2 | -24.2 | 11.5 | 14.0 | — | — |
| Price/book | 20.3 | 8.1 | 0.4 | 2.2 | -5.3 | 2.2 |
| Dividend yield | — | — | 3.64% | — | — | — |
| 1-year change | +176.28% | +87.28% | −16.67% | −51.49% | −33.33% | −47.12% |
| Today | +5.86% | +2.76% | +3.64% | −1.46% | +2.74% | −1.82% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 20 min.
Latest news
All GKOS news ›Glaukos Announces Participation in Upcoming Investor Conferences
The National Law Review Glaukos Announces Participation in Upcoming Investor Conferences ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on no
Glaukos Chief Development Officer Sold Shares Worth Over $10M
TradingView Glaukos Chief Development Officer Sold Shares Worth Over $10M Chief Development Officer Tomas Navratil, an officer of Glaukos, sold 44,436 shares of common stock in four transactions on October 30, 2026, at weighted average p
Transcript : Glaukos Corporation, Q3 2026 Earnings Call, Oct 28, 2026
Presentation Operator MessageOperator Welcome to Glaukos Corporation's Third Quarter 2026 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, Transcript : Glaukos Corporation, Q3 2026…
Truist Adjusts Price Target on Glaukos to $255 From $215, Maintains Buy Rating
Glaukos has an average rating of buy and mean price target of $220.62, according to analysts polled by FactSet. ... Medical Equipment, Supplies & Distribution Truist Adjusts Price Target on Glaukos to $255 From $215, Maintains Buy Rating…
Glaukos Corporation(NYSE: GKOS) added to S&P 400
Glaukos Corporation added to S&P 400... Medical Equipment, Supplies & Distribution Glaukos Corporation(NYSE:GKOS) added to S&P 400
Glaukos Posts Record Q3 Net Sales, Raises Sales Guidance
ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, released third quarter 2026 financial results on Wednesday for the period ending September 30, 2026.
Glaukos (NYSE:GKOS) Price Target Raised to $234.00
Posted by Kim Johansen on Nov 1st, 2026 Glaukos (NYSE:GKOS – Free Report) had its price objective lifted by BTIG Research from $205.00 to $234.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating…
Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
Glaukos (GKOS +32.58%) raised its 2026 sales forecast to $775 million to $785 million and set a preliminary 2027 target of $1 billion. Shares rose about 31% in midday trading. Third-quarter sales jumped 58% to about $211 million. The…
Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat
Glaukos Corporation stocks have been trading up by 33.65 percent amid strong investor optimism surrounding its latest clinical advancements. GKOS has turned into a textbook momentum chart after its earnings shocker. On 2026/10/28, Glaukos…
Glaukos Up 17% in After-Hours Following Record Q3 Results
Raises 2026 net sales guidance Revenue increased 58% to $211 million, coming in above the $168.8 million analyst estimate. “Our record third quarter results reflect successful global execution across our key global commercial and…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com21
- seekingalpha.com6
- timothysykes.com3
- biospace.com2
- fool.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 54 articles, not a forecast.